<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161482</url>
  </required_header>
  <id_info>
    <org_study_id>scP-01-007</org_study_id>
    <nct_id>NCT04161482</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability</brief_title>
  <official_title>An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>scPharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Data Services, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSSi Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>scPharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous&#xD;
      infusions of Furoscix.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Furoscix 80 mg will be administered as a subcutaneous infusion following a step-wise decrease&#xD;
      in infusion times starting with a 5 hour infusion time. Subsequent cohorts will enroll&#xD;
      following a safety assessment of the prior cohort. While maintaining the 80 mg dose, infusion&#xD;
      time will ultimately be reduced to 30 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Actual">June 26, 2020</completion_date>
  <primary_completion_date type="Actual">June 24, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The initial cohort (Cohort 1) will receive 80 mg (10 mL) with a bi-phasic delivery profile over 5 hours.&#xD;
Cohort 2a will evaluate a 2-hour infusion and Cohort 2b will be a bi-phasic delivery over 2 hours.&#xD;
Cohorts 3 and 4 will deliver the Furoscix over one hour and 30 minutes, respectively.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infusion Site Pain (11 Point Pain Scale)</measure>
    <time_frame>8 hours</time_frame>
    <description>Assessment of pain will be conducted upon placement of the subcutaneous (SC) needle, upon activation of SC infusion and periodically during the infusion and post-infusion completion for up to 8 hours after the start of the infusion using a standardized 11 point pain scale. Score will range from 0 to 10, where zero is equivalent to no pain and 10 is equivalent to the worst possible pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse Events)</measure>
    <time_frame>Hours 1-8 and at the 24-48 hour follow up visit.</time_frame>
    <description>Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) will be assessed from the start of study drug administration through 24-48 hours after the start of the infusion.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort One</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A bi-phasic delivery over 5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous infusion over 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bi-phasic delivery over 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous infusion over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous infusion over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide 80 mg (8 mg/mL)</intervention_name>
    <description>Furoscix will be administered as a subcutaneous infusion.</description>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort One</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects are eligible for inclusion only if all of the following criteria are met:&#xD;
&#xD;
          1. An Institutional Review Board (IRB) approved informed consent is signed and dated&#xD;
             prior to any study-related activities.&#xD;
&#xD;
          2. Male and female Subjects 45-80 years of age.&#xD;
&#xD;
          3. Have the ability to understand the requirements of the study and is willing to comply&#xD;
             with all study procedures.&#xD;
&#xD;
          4. In the opinion of the investigator, able to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A Subject is not eligible for inclusion if any of the following criteria apply:&#xD;
&#xD;
          1. Receipt of loop diuretics (furosemide, bumetanide or torsemide) or thiazide diuretics&#xD;
             (hydrochlorothiazide or metolazone) within 24 hours of study drug.&#xD;
&#xD;
          2. Receipt of potassium-sparing diuretics (spironolactone, amiloride) or oral calcium,&#xD;
             potassium or magnesium supplements (including multi-vitamins) within 24 hours of study&#xD;
             drug.&#xD;
&#xD;
          3. History of allergy to furosemide, sulfonamides or other loop diuretics.&#xD;
&#xD;
          4. Any skin conditions currently requiring medical therapy.&#xD;
&#xD;
          5. History of diabetes.&#xD;
&#xD;
          6. Presence or need for urinary catheterization, urinary tract abnormality or disorder&#xD;
             interfering with urination.&#xD;
&#xD;
          7. Serum sodium &lt;130 mEq/L at screening.&#xD;
&#xD;
          8. Serum potassium &lt; 3.5 or &gt; 5.5 mEq/L at screening.&#xD;
&#xD;
          9. Serum magnesium &lt; 1.5 or &gt; 2.5 mEq/L at screening.&#xD;
&#xD;
         10. Serum chloride &lt; 96 or &gt; 106 mEq/L at screening.&#xD;
&#xD;
         11. Serum calcium &lt; 8.5 or &gt; 10.5 mg/dL at screening.&#xD;
&#xD;
         12. Estimated Glomerular Filtration Rate (GFR) &lt; 30 mL/min/1.73 m2 by simplified&#xD;
             Modification of Diet in Renal Disease (sMDRD) equation at screening.&#xD;
&#xD;
         13. Systolic BP (SBP) &lt; 90 mm Hg at screening or baseline.&#xD;
&#xD;
         14. Heart rate &gt; 110 beats per minute (BPM) at screening or baseline.&#xD;
&#xD;
         15. History of tinnitus or hearing impairment, including deafness.&#xD;
&#xD;
         16. Temperature &gt; 38°C (oral or equivalent) at screening or baseline.&#xD;
&#xD;
         17. Blood alcohol concentration &gt; 2 mg/dL (0.02%) at screening or baseline.&#xD;
&#xD;
         18. Female Subject who is pregnant or lactating.&#xD;
&#xD;
         19. History of major abdominal surgery affecting the needle placement site.&#xD;
&#xD;
         20. History of benign prostatic hyperplasia (BPH), prostatitis or prostate cancer.&#xD;
&#xD;
         21. Urinary retention due to bladder emptying disorders and/or urethral narrowing.&#xD;
&#xD;
         22. History of liver disease, cirrhosis, or ascites.&#xD;
&#xD;
         23. Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema,&#xD;
             etc.&#xD;
&#xD;
         24. Allergies and/or sensitivities to adhesive bandages or medical tape.&#xD;
&#xD;
         25. Any surgical or medical condition which in the opinion of the Investigator may&#xD;
             interfere with participation in the study or which may affect the outcome of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Arora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aventiv Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aventiv Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>42313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

